RomerillDBToyodaAYBrodeurBE. Albumin utilization in cardiac surgery after transition to hydroxyethyl starch 130/0.4. J Pharm Pract. 2012;25(6):606–610.
2.
MyburghJAFinferSBellomoR. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367(20):1901–1911.
3.
PernerAHaaseNGuttormsenAB. Hydroxyethyl starch 130/0.4 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;367(2):124–134.
4.
NavickisRJHaynesGRWilkesMM. Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analysis of randomized trials. J Thorac Cardiovasc Surg. 2012;144(1):223–230.
5.
MutterTCRuthCADartAB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. 2013;7:CD007594.
6.
ZarychanskiRAbou-SettaAMTurgeonAF. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA. 2013;309(7):678–688.
7.
WilkesMMNavickisRJSibbaldWJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg. 2001;72(2):527–533.
8.
SchwarzkopfDDoenstT. Perioperative fluid therapy with tetrastarch and gelatin in cardiac surgery-a prospective sequential analysis. Crit Care Med. 2013;41(11):2532–2542.
9.
SedrakyanAGondekKPaltielD. Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest. 2003;123(6):1853–1857.
10.
BellmannRFeistritzerCWiedermannCJ. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. Clin Pharmacokinet. 2012;51(4):225–236.
11.
SchortgenFLacheradeJCBruneelF. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet. 2001;357(9260):911–916.
12.
GattasDJDanAMyburghJ. Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med. 2013;39(4):558–568.
13.
HerwaldtLASwartzendruberSKEdmondMB. The epidemiology of hemorrhage related to cardiothoracic operations. Infect Control Hosp Epidemiol. 1998;19(1):9–16.
14.
Food and Drug Administration. FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. 2013. www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm. Accessed November 11, 2013.
15.
European Medicines Agency. PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients: HES will be available in restricted patient populations. 2013. www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/10/WC500151964.pdf. Accessed November 11, 2013.
